Supplementary Figure 4 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors

Authors :: Patricia M. LoRusso
Dale Miles
A. Douglas Laird
Rodrigo Ruiz-Soto
Coumaran Egile
Weiliang Shi
José Baselga
Anthony W. Tolcher
Amita Patnaik
Ben Markman
Josep Tabernero
Kyriakos P. Papadopoulos
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: PDF file - 1779KB, Supplementary Figure 4. Effect of SAR245409 on Skin Lesions of a Ductal Breast Carcinoma Patient.

Full Text Access

Tools